香港股市 已收市

NeoGenomics, Inc. (NEO)

NasdaqCM - NasdaqCM 即時價格。貨幣為 USD。
加入追蹤清單
13.93+0.06 (+0.43%)
收市:04:00PM EDT
14.02 +0.09 (+0.65%)
收市後: 05:19PM EDT

NeoGenomics, Inc.

9490 NeoGenomics Way
Fort Myers, FL 33912
United States
239 768 0600
https://www.neogenomics.com

版塊Healthcare
行業Diagnostics & Research
全職員工2,100

高階主管

名稱頭銜支付行使價出生年份
Mr. Christopher Michael Smith BScCEO & Director2.86M1963
Mr. Jeffrey S. Sherman M.B.A.Chief Financial Officer1.17M1966
Mr. Vishal SikriPresident of Advanced Diagnostics1.08M1976
Ms. Melody Harris Esq., J.D.President & COO of Informatics1.4M1967
Mr. Warren StoneChief Commercial Officer1.42M1973
Mr. Gregory D. AunanChief Accounting Officer1969
Ms. Kendra SweeneyVice President of Investor Relations & Communications
Ms. Alicia OlivoExecutive VP of Business Development, General Counsel & Corporate Secretary1984
Mr. Hutan Hashemi J.D.Chief Compliance Officer1979
Dr. Derek Lyle M.D.Chief Medical Officer
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

公司管治

截至 2024年6月29日 止,NeoGenomics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中:4;董事會:2;股東權利:3;現金賠償:10。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。